Soxgliflozin in the treatment of patients with diabetes and decompensated heart failure
- Monkeypox mRNA Vaccine Competition: U.S. vs. China
- Can an universal mRNA flu vaccine be against all 20 virus subtypes?
- Harvard found why high-protein diet improves sleep quality
- Will cancer vaccines be the direction of curing cancer?
- Challenges and Prospects of TCR-T Treatment for Solid Tumors
- What are NK (Natural killer) cell biological characteristics?
Soxgliflozin in the treatment of patients with diabetes and decompensated heart failure
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- COVID-19 has been confirmed to cause DNA damage and cellular aging
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
Soxgliflozin in the treatment of patients with diabetes and decompensated heart failure.
Recently, the “New England Journal” (NEJM) published online a SOLOIST-WHF trial study published by the Deepak Bhatt research team of the Cardiovascular Center of Harvard Brigham and Women’s Hospital.
2 Inhibitors can effectively reduce the incidence of combined events of cardiac death, hospitalization and emergency visits due to heart failure in the treatment of patients with diabetes and decompensated heart failure.
Image source: NEJM
Previous studies have shown that sodium-glucose cotransporter-2 inhibitors such as Soxaggliflozin can reduce the hospitalization rate and cardiogenic mortality of patients with stable heart failure.
However, the safety and effectiveness of the drug in the treatment of patients with diabetes and decompensated heart failure are still unknown.
The trial is a three-phase, double-blind, randomized, placebo-controlled trial.
The primary endpoint of the trial was originally designed to be the total number of first cardiovascular deaths or hospitalizations due to heart failure, which was later changed to cardiac deaths, hospitalizations due to heart failure and emergency department visits.
A total of 1,222 patients were included in the study, of which 608 were assigned to the Soxgliflozin group and 614 were assigned to the placebo group. During a median 9-month period, 245 patients in the Soxgliflozin group and 355 patients in the placebo group had a major outcome event.
The number of events in the Soxgliflozin group was lower than that in the placebo group (51.0 VS 76.3; hazard ratio, 0.67; 95% confidence interval, 0.52 to 0.85; P<0.001).
There was no statistical difference between the two groups in the number of cardiogenic deaths and the proportion of all-cause deaths per 100 patient-years.
Soxgliflozin in the treatment of patients with diabetes and decompensated heart failure
(source:internet, reference only)
Disclaimer of medicaltrend.org
